At any time, most cancer patients are receiving a treatment that does not significantly benefit them while they endure bodily and financial toxicity. Aiming to guide each patient to the most optimal treatment, precision medicine ...
Dec 20, 2022
0
63
Researchers at The Tisch Cancer Institute at Mount Sinai have identified a treatment that is effective and safer than the standard of care for a serious, and sometimes fatal, side effect of bone marrow transplant in cancer ...
Dec 14, 2022
0
5
The incidence of a rare cancer, anaplastic large-cell lymphoma (ALCL), has surged in recent years, possibly because of the growing use of textured breast implants. Considering this trend, some breast cancer patients who undergo ...
Dec 2, 2022
0
37
As doctors work toward developing more personalized cancer care, a new study looks at whether lung cancer patients can miss a few days of radiation treatment and make them up with a higher dose.
Oct 25, 2022
0
12
When a man has cancer in an area that affects sexual function, his doctor is likely to discuss it with him.
Oct 25, 2022
0
2
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. ...
Oct 24, 2022
0
5
Continued treatment for patients with cancer near end-of-life delays conversations about goals of care and hospice enrollment, escalates costs, and may adversely affect the quality of care patients receive. Accordingly, over ...
Oct 21, 2022
0
36
In a recent University of Kentucky Markey Cancer Center clinical trial, patients with advanced cancer experienced improved outcomes when their treatments were directed by a molecular tumor board.
Sep 22, 2022
0
18
Using the wrong mathematical formula to assess heartbeat rhythms may lead oncologists to inappropriately stop life-saving chemotherapy, according to research findings from UNC Lineberger Comprehensive Cancer Center scientists. ...
Sep 22, 2022
0
16
Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse, according ...
Sep 14, 2022
0
9
